Interpace Biosciences, Inc. (IDXG)
| Market Cap | 14.85M |
| Revenue (ttm) | 41.86M |
| Net Income (ttm) | -12.98M |
| Shares Out | 4.23M |
| EPS (ttm) | -3.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,001 |
| Open | 3.50 |
| Previous Close | 3.46 |
| Day's Range | 3.50 - 3.52 |
| 52-Week Range | 2.76 - 10.51 |
| Beta | 1.14 |
| Analysts | Sell |
| Price Target | 11.22 (+219.3%) |
| Earnings Date | May 16, 2022 |
About IDXG
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. ...
Financial Performance
In 2020, IDXG's revenue was $32.40 million, an increase of 33.77% compared to the previous year's $24.22 million. Losses were -$26.45 million, -1.08% less than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for IDXG stock is "Sell." The 12-month stock price forecast is 11.22, which is an increase of 219.29% from the latest price.
News
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and...
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended...
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was termina...
Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director
PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, P...
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering
PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped R...
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
Proceeds to be used to fund the organic growth and prospective product line acquisitions
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equi...
PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $8...
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determi...
PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecu...
Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Bio...
PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecu...
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7...
Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates
Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why
Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma...
Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services
Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer a...
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 an...
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally pr...
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in ...
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGe...
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agre...
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 20...
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
Part of Company's Site Consolidation and Cost Savings Measures
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announ...
Interpace Biosciences Announces Impending Delisting from Nasdaq
PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February ...
Interpace Biosciences Announces Path Forward in Letter to Shareholders
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders:
Interpace Biosciences Announces CFO Leadership Transition
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has app...
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, an...